NewAmsterdam Pharma Co NV (FRA:KH6) EBIT : €-162.72 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV EBIT?

NewAmsterdam Pharma Co NV's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was €-87.39 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was €-162.72 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NewAmsterdam Pharma Co NV's annualized ROC % for the quarter that ended in Dec. 2023 was -285.06%. NewAmsterdam Pharma Co NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -169,683.50%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NewAmsterdam Pharma Co NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -13.10%.

NewAmsterdam Pharma Co NV EBIT Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV EBIT Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-5.47

-36.62

-21.10

-162.23

NewAmsterdam Pharma Co NV Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial			-26.77	54.05	-75.03	-75.33	-87.39

Competitive Comparison of NewAmsterdam Pharma Co NV's EBIT

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NewAmsterdam Pharma Co NV's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's EV-to-EBIT falls into.

NewAmsterdam Pharma Co NV EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-162.72 Mil.

NewAmsterdam Pharma Co NV (FRA:KH6) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NewAmsterdam Pharma Co NV's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-174.96 * ( 1 - -0.03% )	/	( (99.619	+	23.17)	/ 2 )
=	-175.012488	/	61.3945
=	-285.06 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	472.542	-	20.918	-	( 384.67	-	max(0, 38.452	-	390.457	+	384.67	))
=	99.619

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	318.288	-	22.867	-	( 312.193	-	max(0, 45.756	-	318.007	+	312.193	))
=	23.17

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

NewAmsterdam Pharma Co NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-174.774	/	( ( (0.113 + max(-38.386, 0))	+	(0.093 + max(-41.612, 0)) )	/	2 )
=	-174.774	/	( ( 0.113	+	0.093 )	/	2 )
=	-174.774	/	0.103
=	-169,683.50 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.00099999999997635)	-	(20.918	+	9.72	+	7.749)
=	-38.386

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.089)	-	(22.867	+	8.2	+	14.634)
=	-41.612

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NewAmsterdam Pharma Co NV's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-162.716	/	1241.896
	=	-13.10 %

NewAmsterdam Pharma Co NV EBIT Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV (FRA:KH6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

NAMS:USA KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (FRA:KH6) Headlines

No Headlines